Picture of Crispr Therapeutics AG logo

CRSP Crispr Therapeutics AG Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapNeutral

Annual cashflow statement for Crispr Therapeutics AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-68.4-16566.9-349378
Depreciation
Non-Cash Items20.654.733.567.9116
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-25.410.6-48.433.426.9
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities-70.1-96.256.7-238539
Capital Expenditures-7.81-2.77-6.68-18.4-81.7
Purchase of Fixed Assets
Other Investing Cash Flow Items-0.508.01-523-954
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-8.31-2.771.32-541-1,035
Financing Cash Flow Items0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities2.613164311,016251
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-75.8217489237-246

Or unlock with your email

Or unlock with your email